uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Exploring the obstacles to implementing economic mechanisms to stimulate antibiotic research and development: a mulit-actor and system-level analysis
Uppsala University, Disciplinary Domain of Science and Technology, Technology, Department of Engineering Sciences, Industrial Engineering & Management.
Uppsala University, Disciplinary Domain of Humanities and Social Sciences, Faculty of Social Sciences, Department of Business Studies.
Univ Hosp Geneva, Infect Control Program, Geneva, Switzerland; Fac Med, Geneva, Switzerland.
Univ Hosp Geneva, Infect Control Program, Geneva, Switzerland; Fac Med, Geneva, Switzerland; London Sch Econ & Polit Sci, London, England.
Show others and affiliations
2016 (English)In: American Journal of Law & Medicine, ISSN 0098-8588, Vol. 42, 451-486 p.Article in journal (Refereed) Published
Abstract [en]

This Article examines the potential stakeholder-related obstacles hindering the implementation of mechanisms to re-ignite the development of novel antibiotics. Proposed economic models and incentives to drive such development include: Public Funding of Research and Development (R&D), Tax Incentives, Milestone Prizes, End Payments, Intellectual Property (IP) and Exclusivity Extensions, Pricing and Reimbursement Incentives, Product Development Partnerships (PDPs), and the Options Market for Antibiotics model. Drawing on personal experience and understanding of the antibiotic field, as well as stakeholder consultation and numerous expert meetings within the DRIVE-AB project and Uppsala Health Summit 2015, the Authors identify obstacles attributable to the following actors: Universities and Research Institutes, Small and Medium-sized Enterprises (SMEs), Large Pharmaceutical Companies, Marketing Approval Regulators, Payors, Healthcare Providers, National Healthcare Authorities, Patients, and Supranational Institutions. The analysis also proposes a characterization and ranking of the difficulty associated with implementing the reviewed mechanisms. Public Funding of R&D, Pricing and Reimbursement Incentives, and PDPs are mechanisms expected to meet highly systemic barriers (i.e., obstacles across the entire antibiotic value chain), imposing greater implementation challenges in that they require convincing and involving several motivationally diverse actors in order to have much effect.

Place, publisher, year, edition, pages
Boston: Boston University School of Law , 2016. Vol. 42, 451-486 p.
National Category
Social Sciences Engineering and Technology
Research subject
Business Studies; Engineering Science with specialization in industrial engineering and management
Identifiers
URN: urn:nbn:se:uu:diva-301113DOI: 10.1177/0098858816658276ISI: 000380962100009OAI: oai:DiVA.org:uu-301113DiVA: diva2:953634
Funder
EU, European Research Council
Available from: 2016-08-18 Created: 2016-08-18 Last updated: 2016-10-26

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Baraldi, EnricoCiabuschi, FrancescoWaluszewski, Alexandra
By organisation
Industrial Engineering & ManagementDepartment of Business StudiesScience and Technology Studies Center
In the same journal
American Journal of Law & Medicine
Social SciencesEngineering and Technology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 861 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf